Nombre del producto:5-chloro-2-(piperidin-4-yl)pyrimidine

IUPAC Name:5-chloro-2-(piperidin-4-yl)pyrimidine

CAS:944903-10-0
Fórmula molecular:C9H12ClN3
Pureza:95%+
Número de catálogo:CM466825
Peso molecular:197.67

Unidad de embalaje Stock disponible Precio($) Cantidad
CM466825-1g 5-6 Weeks Ĝţǟǎ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :944903-10-0
Fórmula molecular:C9H12ClN3
Punto de fusión:-
Código de sonrisas:ClC1=CN=C(N=C1)C1CCNCC1
Densidad:
Número de catálogo:CM466825
Peso molecular:197.67
Punto de ebullición:
Nº Mdl:MFCD10697164
Almacenamiento:

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Nerandomilast
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.